Compare ALEMBIC with Cipla - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC vs CIPLA - Comparison Results

ALEMBIC     Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

CIPLA 
   Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALEMBIC CIPLA ALEMBIC/
CIPLA
 
P/E (TTM) x 57.8 35.6 162.4% View Chart
P/BV x 5.0 4.1 120.7% View Chart
Dividend Yield % 0.2 0.5 41.3%  

Financials

 ALEMBIC   CIPLA
EQUITY SHARE DATA
    ALEMBIC
Mar-18
CIPLA
Mar-20
ALEMBIC/
CIPLA
5-Yr Chart
Click to enlarge
High Rs72586 12.3%   
Low Rs34357 9.5%   
Sales per share (Unadj.) Rs4.7207.0 2.3%  
Earnings per share (Unadj.) Rs6.118.6 32.8%  
Cash flow per share (Unadj.) Rs6.233.2 18.8%  
Dividends per share (Unadj.) Rs0.204.00 5.0%  
Dividend yield (eoy) %0.40.8 44.5%  
Book value per share (Unadj.) Rs40.7195.5 20.8%  
Shares outstanding (eoy) m267.03806.35 33.1%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x11.32.3 495.0%   
Avg P/E ratio x8.725.3 34.2%  
P/CF ratio (eoy) x8.514.2 59.7%  
Price / Book Value ratio x1.32.4 54.0%  
Dividend payout %3.321.5 15.2%   
Avg Mkt Cap Rs m14,139379,912 3.7%   
No. of employees `000NA25.8 0.0%   
Total wages/salary Rs m20730,270 0.7%   
Avg. sales/employee Rs ThNM6,459.6-  
Avg. wages/employee Rs ThNM1,171.2-  
Avg. net profit/employee Rs ThNM580.2-  
INCOME DATA
Net Sales Rs m1,255166,949 0.8%  
Other income Rs m3703,442 10.8%   
Total revenues Rs m1,625170,391 1.0%   
Gross profit Rs m11132,060 0.3%  
Depreciation Rs m3811,747 0.3%   
Interest Rs m21,974 0.1%   
Profit before tax Rs m44221,782 2.0%   
Minority Interest Rs m0-475 0.0%   
Prior Period Items Rs m1,2120-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m246,312 0.4%   
Profit after tax Rs m1,63014,995 10.9%  
Gross profit margin %8.919.2 46.1%  
Effective tax rate %5.429.0 18.7%   
Net profit margin %129.89.0 1,445.7%  
BALANCE SHEET DATA
Current assets Rs m1,867117,038 1.6%   
Current liabilities Rs m59143,931 1.3%   
Net working cap to sales %101.643.8 232.1%  
Current ratio x3.22.7 118.5%  
Inventory Days Days9496 98.5%  
Debtors Days Days7485 86.4%  
Net fixed assets Rs m1,791107,424 1.7%   
Share capital Rs m5341,613 33.1%   
"Free" reserves Rs m10,324156,018 6.6%   
Net worth Rs m10,858157,630 6.9%   
Long term debt Rs m4123,693 0.2%   
Total assets Rs m11,591236,626 4.9%  
Interest coverage x260.912.0 2,167.4%   
Debt to equity ratio x00.2 2.5%  
Sales to assets ratio x0.10.7 15.3%   
Return on assets %14.17.2 196.3%  
Return on equity %15.09.5 157.8%  
Return on capital %15.212.8 118.3%  
Exports to sales %1.533.0 4.7%   
Imports to sales %21.00-   
Exports (fob) Rs m1955,175 0.0%   
Imports (cif) Rs m263NA-   
Fx inflow Rs m1956,036 0.0%   
Fx outflow Rs m2646,764 3.9%   
Net fx Rs m-24449,272 -0.5%   
CASH FLOW
From Operations Rs m23630,685 0.8%  
From Investments Rs m-2241,040 -21.5%  
From Financial Activity Rs m-27-29,488 0.1%  
Net Cashflow Rs m-152,340 -0.6%  

Share Holding

Indian Promoters % 64.0 16.0 400.0%  
Foreign collaborators % 0.0 20.8 -  
Indian inst/Mut Fund % 0.2 12.2 1.6%  
FIIs % 9.7 23.7 40.9%  
ADR/GDR % 0.0 1.1 -  
Free float % 26.1 26.2 99.6%  
Shareholders   54,701 161,166 33.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALEMBIC With:   UNICHEM LAB  SUN PHARMA  PIRAMAL ENTERPRISES  GLENMARK PHARMA  AUROBINDO PHARMA  

Compare ALEMBIC With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Plunges 746 Points; Banking & Metal Stocks Bleed(Closing)

Indian share markets witnessed huge selling pressure today and extended losses as the session progressed, dragged down by heavy selling in metal and banking stocks.

Related Views on News

CIPLA 2019-20 Annual Report Analysis (Annual Result Update)

Nov 4, 2020 | Updated on Nov 4, 2020

Here's an analysis of the annual report of CIPLA for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CIPLA. Also includes updates on the valuation of CIPLA.

CIPLA Announces Quarterly Results (1QFY21); Net Profit Up 21.4% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, CIPLA has posted a net profit of Rs 6 bn (up 21.4% YoY). Sales on the other hand came in at Rs 43 bn (up 7.2% YoY). Read on for a complete analysis of CIPLA's quarterly results.

ALEMBIC LTD Announces Quarterly Results (1QFY21); Net Profit Up 3.5% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, ALEMBIC LTD has posted a net profit of Rs 21 m (up 3.5% YoY). Sales on the other hand came in at Rs 131 m (down 49.7% YoY). Read on for a complete analysis of ALEMBIC LTD's quarterly results.

CIPLA Announces Quarterly Results (4QFY20); Net Profit Down 35.1% (Quarterly Result Update)

May 19, 2020 | Updated on May 19, 2020

For the quarter ended March 2020, CIPLA has posted a net profit of Rs 2 bn (down 35.1% YoY). Sales on the other hand came in at Rs 44 bn (down 0.6% YoY). Read on for a complete analysis of CIPLA's quarterly results.

CIPLA Announces Quarterly Results (3QFY20); Net Profit Up 9.4% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, CIPLA has posted a net profit of Rs 4 bn (up 9.4% YoY). Sales on the other hand came in at Rs 44 bn (up 9.1% YoY). Read on for a complete analysis of CIPLA's quarterly results.

More Views on News

Most Popular

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

A Rare Chance to Invest in Potential Multibaggers in 2021(Profit Hunter)

Jan 11, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC SHARE PRICE


Jan 22, 2021 (Close)

TRACK ALEMBIC

  • Track your investment in ALEMBIC with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ALEMBIC - AUROBINDO PHARMA COMPARISON

COMPARE ALEMBIC WITH

MARKET STATS